Table 2.
Characteristics of Hospitalized Adult Patients Admitted Between July 1, 2017, and February 28, 2020, by HARVI Statusa
| Variable | w/o HARVI (N=111,279), No. (%)b | Any HARVI (N=236), No. (%)b | Adenovirus (N=5), No. (%)b | ccCoV (N=29), No. (%)b | hMPV (N=21), No. (%)b | Influenza A (N=50), No. (%)b | Influenza B (N=9), No. (%)b | PIV (N=26), No. (%)b | RSV (N=24), No. (%)b | hRV/EV (N=84), No. (%)b |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, median y (IQR) | 57 (36–69) | 60 (43–71)* | 48 (46–61) | 60 (44–71) | 62 (43–71) | 65 (53–76)** | 51 (40–61) | 60 (36–74) | 60 (52–70) | 57 (36–68) |
| Sex | *** | * | *** | |||||||
| Female | 60,930 (55) | 103 (44) | 3 (60) | 14 (48) | 6 (29) | 24 (48) | 6 (67) | 13 (50) | 10 (42) | 31 (37) |
| Male | 50,349 (45) | 133 (56) | 2 (40) | 15 (52) | 15 (71) | 26 (52) | 3 (33) | 13 (50) | 14 (58) | 53 (63) |
| Race | ||||||||||
| NH Asian | 3,060 (3) | 2 (1) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| NH Black | 13,246 (12) | 27 (11) | 2 (40) | 2 (7) | 5 (24) | 5 (10) | 1 (11) | 1 (4) | 4 (17) | 9 (11) |
| NH White | 88,628 (80) | 191 (81) | 3 (60) | 23 (79) | 15 (71) | 42 (84) | 7 (78) | 24 (92) | 20 (83) | 66 (79) |
| Other/Unknown/Missing | 6,345 (6) | 16 (7) | 0 (0) | 4 (14) | 1 (5) | 2 (4) | 1 (11) | 1 (4) | 0 (0) | 8 (10) |
| Charlson score, median (IQR) | 2 (0–6) | 5 (3–8)*** | 9 (9–10)** | 4 (2–8)** | 7 (4–10)*** | 6 (3–8)*** | 2 (2–3) | 4 (3–6)* | 6 (4–9)*** | 4 (2–6)*** |
| Chronic condition | ||||||||||
| Myocardial infarction | 14,262 (13) | 46 (19)** | 2 (40) | 6 (21) | 6 (29)* | 10 (20) | 1 (11) | 6 (23) | 6 (25) | 12 (14) |
| Congestive heart failure | 24,680 (22) | 107 (45)*** | 1 (20) | 12 (41)* | 15 (71)*** | 27 (54)*** | 4 (44) | 13 (50)*** | 11 (46)** | 30 (36)** |
| Peripheral vascular disease | 18,331 (16) | 56 (24)** | 2 (40) | 2 (7) | 9 (43)** | 15 (30)** | 0 (0) | 5 (19) | 8 (33)* | 17 (20) |
| Cerebrovascular disease | 12,260 (11) | 51 (22)*** | 3 (60)* | 6 (21) | 7 (33)** | 15 (30)*** | 0 (0) | 4 (15) | 5 (21) | 14 (17) |
| Chronic pulmonary disease | 28,899 (26) | 85 (36)*** | 3 (60) | 9 (31) | 11 (52)** | 19 (38) | 6 (67)* | 8 (31) | 8 (33) | 27 (32) |
| Rheumatoid disease | 5,622 (5) | 18 (8) | 1 (20) | 4 (14) | 1 (5) | 3 (6) | 1 (11) | 0 (0) | 3 (12) | 6 (7) |
| Peptic ulcer disease | 4,160 (4) | 18 (8)** | 1 (20) | 4 (14)* | 1 (5) | 4 (8) | 0 (0) | 3 (12) | 1 (4) | 7 (8)* |
| Liver disease | 13,658 (12) | 42 (18)** | 2 (40) | 5 (17) | 6 (29)* | 10 (20) | 1 (11) | 3 (12) | 8 (33)** | 11 (13) |
| Diabetes | 27,799 (25) | 86 (36)*** | 3 (60) | 11 (38) | 9 (43) | 23 (46)*** | 2 (22) | 10 (38) | 10 (42) | 21 (25) |
| Hemiplegia or paraplegia | 5,430 (5) | 16 (7) | 1 (20) | 1 (3) | 1 (5) | 2 (4) | 0 (0) | 2 (8) | 6 (25)*** | 5 (6) |
| Renal disease | 26,179 (24) | 103 (44)*** | 4 (80)* | 11 (38) | 16 (76)*** | 22 (44)*** | 3 (33) | 11 (42)* | 9 (38) | 34 (40)*** |
| Cancer | 27,401 (25) | 110 (47)*** | 3 (60) | 15 (52)*** | 9 (43) | 15 (30) | 4 (44) | 13 (50)** | 11 (46)* | 45 (54)*** |
| ≥2 SIRS criteria | 27,079 (24) | 83 (35)*** | 2 (40) | 14 (48)** | 7 (33) | 16 (32) | 2 (22) | 10 (38) | 8 (33) | 28 (33)* |
| Study period | * | |||||||||
| 2017–2018 | 41,519 (37) | 97 (41) | 3 (60) | 14 (48) | 9 (43) | 23 (46) | 6 (67) | 12 (46) | 8 (33) | 30 (36) |
| 2018–2019 | 42,199 (38) | 78 (33) | 1 (20) | 12 (41) | 8 (38) | 9 (18) | 1 (11) | 9 (35) | 9 (38) | 31 (37) |
| 2019–2020 | 27,561 (25) | 61 (26) | 1 (20) | 3 (10) | 4 (19) | 18 (36) | 2 (22) | 5 (19) | 7 (29) | 23 (27) |
| Admission Month | *** | ** | ** | *** | *** | *** | ||||
| Jul | 10,590 (10) | 5 (2) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 1 (4) | 0 (0) | 4 (5) |
| Aug | 10,976 (10) | 7 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (12) | 0 (0) | 4 (5) |
| Sep | 10,230 (9) | 20 (8) | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 3 (12) | 0 (0) | 16 (19) |
| Oct | 10,997 (10) | 15 (6) | 0 (0) | 1 (3) | 1 (5) | 1 (2) | 0 (0) | 1 (4) | 1 (4) | 11 (13) |
| Nov | 10,194 (9) | 16 (7) | 1 (20) | 3 (10) | 3 (14) | 1 (2) | 0 (0) | 2 (8) | 2 (8) | 7 (8) |
| Dec | 10,126 (9) | 34 (14) | 0 (0) | 6 (21) | 4 (19) | 5 (10) | 2 (22) | 4 (15) | 8 (33) | 6 (7) |
| Jan | 10,550 (9) | 41 (17) | 2 (40) | 1 (3) | 2 (10) | 21 (42) | 0 (0) | 2 (8) | 6 (25) | 8 (10) |
| Feb | 9,561 (9) | 30 (13) | 0 (0) | 5 (17) | 0 (0) | 13 (26) | 1 (11) | 0 (0) | 4 (17) | 7 (8) |
| Mar | 7,022 (6) | 28 (12) | 1 (20) | 5 (17) | 5 (24) | 6 (12) | 4 (44) | 1 (4) | 3 (12) | 5 (6) |
| Apr | 7,062 (6) | 19 (8) | 0 (0) | 5 (17) | 4 (19) | 0 (0) | 2 (22) | 2 (8) | 0 (0) | 7 (8) |
| May | 7,146 (6) | 10 (4) | 1 (20) | 2 (7) | 0 (0) | 3 (6) | 0 (0) | 3 (12) | 0 (0) | 3 (4) |
| Jun | 6,825 (6) | 11 (5) | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 4 (15) | 0 (0) | 6 (7) |
Note. ccCoV, common-cold coronavirus; HARVI; hospital-associated respiratory virus infection; hMPV, human metapneumovirus; hRV/EV, human rhinovirus–enterovirus; IQR, interquartile range; NH, non-Hispanic; PIV, parainfluenza; RSV, respiratory syncytial virus; SIRS, systemic inflammatory response syndrome.
a
Numbers in the table represent inpatient admissions; individual patients may have been admitted to the hospital multiple times during the study period.
b
Data are no. (%) unless otherwise specified.
*
P < .05 statistically significant difference relative to admissions without HARVI.
**
P < .01 statistically significant difference relative to admissions without HARVI.
***
P < .001 statistically significant difference relative to admissions without HARVI.